MaaT Pharma Reports the First Patient Dosing of MaaT033 in P-IIb Trial for Blood Cancer Patients
Shots:
- The P-IIb (PHOEBUS) clinical trial evaluates the efficacy of MaaT033 vs PBO in patients with blood cancer receiving allo-HSCT. The trial is expected to enroll a total of 387 patients & is expected to be conducted across ~56 clinical investigation sites
- The 1EP of the study include overall survival whereas the 2EPs includes safety, tolerability (before & after allo-HSCT) & the evaluation of the engraftment of beneficial microbial species from MaaT033. The 1EP of the study is expected to be evaluated by YE 2026
- MaaT033 is an oral Microbiome Ecosystem Therapy that contains an anti-inflammatory Butycore species. Earlier in Aug 2023, MaaT033 received the EMA’s ODD as an adjunctive therapy for patients receiving Allo-HSCT
Ref: Businesswire | Image: MaaT Pharma
Related News:- MaaT Pharma Receives Positive Opinion from DSMB for MaaT013 in P-III Trial to Treat Graft Versus Host Disease (GvHD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
